Merck’s Keytruda (pembrolizumab) + Inlyta (axitinib) Receive FDA’s Approval as 1L Treatment for Advanced Renal Cell Carcinoma

 Merck’s Keytruda (pembrolizumab) + Inlyta (axitinib) Receive FDA’s Approval as 1L Treatment for Advanced Renal Cell Carcinoma

Merck’s Keytruda (pembrolizumab) + Inlyta (axitinib) Receive FDA’s Approval as 1L Treatment for Advanced Renal Cell Carcinoma

Shots:

  • The approval is based on P-III KEYNOTE-426 study assessing Keytruda (pembrolizumab, 200mg, q3w up to 24mos.) + Inlyta (axitinib,5mg, bid) vs sunitinib (50mg, qd for 4wks.)  in 861 patients in ratio (1:1) who had not received systemic therapy for advanced RCC
  • The P-III KEYNOTE-426 & median 12.8mos. follow up studies result:  47% reduction in risk of death; 31% reduction in PFS; ORR (59% vs 36%); OS (90% vs 78%); m-PFS (15.1 vs 11.1 mos.); CRR (6% vs  2%); PRR (53% vs 34%)
  • Keytruda (pembrolizumab, IV, 100mg) is a mAb blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 and activating the T lymphocytes. Inlyta (axitinib) is a tyrosine kinase inhibitor and is prescribed to treat advanced kidney cancer

Click here to read full press release/ article | Ref: Merck | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post